Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2025)

Rani Therapeutics Holdings has reported Common Equity over the past 6 years, most recently at $41.5 million for Q4 2025.

  • Quarterly results put Common Equity at $41.5 million for Q4 2025, up 1088.43% from a year ago — trailing twelve months through Dec 2025 was $41.5 million (up 1088.43% YoY), and the annual figure for FY2025 was $41.5 million, up 1088.43%.
  • Common Equity for Q4 2025 was $41.5 million at Rani Therapeutics Holdings, up from -$12.0 million in the prior quarter.
  • Over the last five years, Common Equity for RANI hit a ceiling of $131.7 million in Q3 2021 and a floor of -$123.7 million in Q2 2021.
  • Median Common Equity over the past 5 years was $30.1 million (2023), compared with a mean of $29.8 million.
  • Peak annual rise in Common Equity hit 1088.43% in 2025, while the deepest fall reached 307.32% in 2025.
  • Rani Therapeutics Holdings' Common Equity stood at $121.6 million in 2021, then crashed by 39.12% to $74.0 million in 2022, then crashed by 65.62% to $25.4 million in 2023, then crashed by 86.27% to $3.5 million in 2024, then skyrocketed by 1088.43% to $41.5 million in 2025.
  • The last three reported values for Common Equity were $41.5 million (Q4 2025), -$12.0 million (Q3 2025), and -$9.2 million (Q2 2025) per Business Quant data.